207600-12-2

Upstream product

• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 103343-47-1 3-amino-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 

Downstream Products

• 103343-64-2 (S)-2-Amino-N-((R)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenyl-propionamide 
• 103343-63-1 3(S)-(2(S)-amino-3-phenylpropanoylamino)-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one 
• 103343-65-3 (3R)-3-amino-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 
• 103343-66-4 (S)-3-amino-1-methyl-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 253135-95-4 (S)-3-amino-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2(3H)one 
• 796038-21-6 (R)-3-amino-5-phenyl-1,3-dihydro-2H-benzo[e][1.4]-diazepin-2-one 
• 932108-13-9 (R,S)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenyl-2-(3-phenylthioureido)propionamide 
• 676127-93-8 (S,S)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenyl-2-(3-phenylthioureido)propionamide 
• 932108-22-0 (S)-{3-[3-(2-fluorophenyl)ureido]-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl}acetic acid 
• 932108-21-9 (S)-{3-[3-(2-fluorophenyl)ureido]-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl}acetic acid methyl ester 
• 676128-62-4 C₂₂H₁₇FN₄O₂ 
• 676128-63-5 (S)-1-(2-fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 

Relevant academic research and scientific papers

1,4-Benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate

Respiratory syncytial virus (RSV) is the cause of one-fifth of all lower respiratory tract infections worldwide and is increasingly being recognized as representing a serious threat to patient groups with poorly functioning or immature immune systems. Rac

Methods for Drug Discovery: Development of Potent, Selective, Orally Effecive Cholecystokinin Antagonists

3-(Acylamino)-5-phenyl-2H-1,4-benzodiazepines, antagonists of the peptide hormone cholecystokinin (CCK), are described.Developed by reasoned modification of the known anxiolytic benzodiazepines, these compounds provide highly potent, orally effective ligands selective for peripheral (CCK-A) receptors, with binding affinities approaching or equaling that of the natural ligand CCK-8.The distinction between CCK-A receptors on the one hand and CNS (CCK-B), gastrin, and central benzodiazepine receptors on the other is demonstrated by using the structure-activity profiles of the new compounds.Details of the binding of these agents to CCK-A receptors are examined, and the method of development of these compounds is discussed in terms of its relevance to the general problem of drug discovery.

A NEW AMINE RESOLUTION METHOD AND ITS APPLICATION TO 3-AMINOBENZODIAZEPINES

A new method for the resolution of amines and its application to 3-aminobenzodiazepines 1 is described.The method involves the synthesis and separation of a pair of phenylalanyl amide diastereomers followed by removal of phenylalanine via the Edman degrad